Therapeutic targeting of NOD1 receptors

British Journal of Pharmacology

Volumn 170, Issue 3, 2013, Pages 475-485

  Moreno, L ^a,b   Gatheral, T ^c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

atherosclerosis; endothelium; intestinal immunity; metabolic syndrome; pulmonary immunity; receptor interacting protein 2; septic shock

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CYTOPLASMIC RECEPTOR; GLUCOCORTICOID; GSK 214; GSK 217; HEPTANOYL GAMMA DEXTRO GLUTAMYL 2,6 DIAMINOPIMELOYL DEXTRO ALANINE; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 2; NODITINIB 1; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; PROTEIN NOD1 RECEPTOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; BASAL CELL CARCINOMA; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; ENTEROPATHY; HUMAN; INNATE IMMUNITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN METABOLISM; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; ENDOTHELIUM; INTESTINAL IMMUNITY; METABOLIC SYNDROME; PULMONARY IMMUNITY; RECEPTOR-INTERACTING PROTEIN 2; SEPTIC SHOCK;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MOLECULAR TARGETED THERAPY; NOD1 SIGNALING ADAPTOR PROTEIN; SIGNAL TRANSDUCTION;

EID: 84884578152     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12300     Document Type: Review

References (113)

1. Abreu MT, Fukata M, Arditi M, (2005). TLR signaling in the gut in health and disease. J Immunol 174: 4453-4460.
2. Allison CC, Ferrand J, McLeod L, Hassan M, Kaparakis-Liaskos M, Grubman A, et al. (2013). Nucleotide oligomerization domain 1 enhances IFN-gamma signaling in gastric epithelial cells during Helicobacter pylori infection and exacerbates disease severity. J Immunol 190: 3706-3715.
3. Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermudez-Humaran LG, et al. (2011). Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 3: 559-572.
4. Andraws R, Berger JS, Brown DL, (2005). Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 293: 2641-2647.
5. Berrington WR, Iyer R, Wells RD, Smith KD, Skerrett SJ, Hawn TR, (2010). NOD1 and NOD2 regulation of pulmonary innate immunity to Legionella pneumophila. Eur J Immunol 40: 3519-3527.
6. Bertin J, Nir WJ, Fischer CM, Tayber OV, Errada PR, Grant JR, et al. (1999). Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-kappaB. J Biol Chem 274: 12955-12958.
7. Bouskra D, Brezillon C, Berard M, Werts C, Varona R, Boneca IG, et al. (2008). Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature 456: 507-510.
8. Buchholz KR, Stephens RS, (2008). The cytosolic pattern recognition receptor NOD1 induces inflammatory interleukin-8 during Chlamydia trachomatis infection. Infect Immun 76: 3150-3155.
9. Cartwright N, McMaster SK, Sorrentino R, Paul-Clark M, Sriskandan S, Ryffel B, et al. (2007a). Elucidation of Toll-like receptor and adapter protein signaling in vascular dysfunction induced by gram-positive Staphylococcus aureus or gram-negative Escherichia coli. Shock 27: 40-47.
10. Cartwright N, Murch O, McMaster SK, Paul-Clark MJ, van Heel DA, Ryffel B, et al. (2007b). Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. Am J Respir Crit Care Med 175: 595-603.
11. Chamaillard M, Hashimoto M, Horie Y, Masumoto J, Qiu S, Saab L, et al. (2003). An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 4: 702-707.
12. Chamaillard M, Inohara N, Nunez G, (2004). Battling enteroinvasive bacteria: NOD1 comes to the rescue. Trends Microbiol 12: 529-532.
13. Chaouche-Drider N, Kaparakis M, Karrar A, Fernandez MI, Carneiro LA, Viala J, et al. (2009). A commensal Helicobacter sp. of the rodent intestinal flora activates TLR2 and NOD1 responses in epithelial cells. PLoS ONE 4: e5396.
14. Chatterjee D, Chaudhuri K, (2013). Vibrio cholerae O395 outer membrane vesicles modulate intestinal epithelial cells in a NOD1 protein-dependent manner and induce dendritic cell-mediated Th2/Th17 cell responses. J Biol Chem 288: 4299-4309.
15. Chen GY, Nunez G, (2009). Gut immunity: a NOD to the commensals. Curr Biol 19: R171-R174.
16. Chen GY, Nunez G, (2010). Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10: 826-837.
17. Chen GY, Shaw MH, Redondo G, Nunez G, (2008). The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res 68: 10060-10067.
18. Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, Weiser JN, (2010). Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 16: 228-231.
19. Correa RG, Khan PM, Askari N, Zhai D, Gerlic M, Brown B, et al. (2011). Discovery and characterization of 2-aminobenzimidazole derivatives as selective NOD1 inhibitors. Chem Biol 18: 825-832.
20. Correa RG, Milutinovic S, Reed JC, (2012). Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases. Biosci Rep 32: 597-608.
21. Cuda C, Badawi A, Karmali M, El-Sohemy A, (2012). Effects of polymorphisms in nucleotide-binding oligomerization domains 1 and 2 on biomarkers of the metabolic syndrome and type II diabetes. Genes Nutr 7: 427-435.
22. De Kimpe SJ, Kengatharan M, Thiemermann C, Vane JR, (1995). The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci U S A 92: 10359-10363.
23. Dharancy S, Body-Malapel M, Louvet A, Berrebi D, Gantier E, Gosset P, et al. (2009). Neutrophil migration during liver injury is under nucleotide-binding oligomerization domain 1 control. Gastroenterology 138: 1546-1556, 1556 e1541-1545.
24. Eckmann L, (2006). Sensor molecules in intestinal innate immunity against bacterial infections. Curr Opin Gastroenterol 22: 95-101.
25. El Mokhtari NE, Ott SJ, Nebel A, Simon R, Schreiber S, (2006). A functional variant in the CARD4 gene and risk of premature coronary heart disease. Int J Immunogenet 33: 307-311.
26. Epstein SE, Zhou YF, Zhu J, (1999). Potential role of cytomegalovirus in the pathogenesis of restenosis and atherosclerosis. Am Heart J 138 (5 Pt 2): S476-S478.
27. Erridge C, (2008). The roles of pathogen-associated molecular patterns in atherosclerosis. Trends Cardiovasc Med 18: 52-56.
28. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Peth S, Kopp H, et al. (2002). [Manifestations of atherosclerosis in various vascular regions. Similarities and differences regarding epidemiology, etiology and prognosis]. Med Klin (Munich) 97: 221-228.
29. Feng BS, He SH, Zheng PY, Wu L, Yang PC, (2007). Mast cells play a crucial role in Staphylococcus aureus peptidoglycan-induced diarrhea. Am J Pathol 171: 537-547.
30. Fernandez-Velasco M, Prieto P, Terron V, Benito G, Flores JM, Delgado C, et al. (2012). NOD1 activation induces cardiac dysfunction and modulates cardiac fibrosis and cardiomyocyte apoptosis. PLoS ONE 7: e45260.
31. Ferwerda G, Girardin SE, Kullberg BJ, Le Bourhis L, de Jong DJ, Langenberg DM, et al. (2005). NOD2 and Toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog 1: 279-285.
32. Frantz S, Ertl G, Bauersachs J, (2007). Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 4: 444-454.
33. Fritz JH, Girardin SE, Fitting C, Werts C, Mengin-Lecreulx D, Caroff M, et al. (2005). Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol 35: 2459-2470.
34. Fukazawa A, Alonso C, Kurachi K, Gupta S, Lesser CF, McCormick BA, et al. (2008). GEF-H1 mediated control of NOD1 dependent NF-kappaB activation by Shigella effectors. PLoS Pathog 4: e1000228.
35. Gatheral T, Reed DM, Moreno L, Gough PJ, Votta BJ, Sehon CA, et al. (2012). A key role for the endothelium in NOD1 mediated vascular inflammation: comparison to TLR4 responses. PLoS ONE 7: e42386.
36. Girardin SE, Tournebize R, Mavris M, Page AL, Li X, Stark GR, et al. (2001). CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO Rep 2: 736-742.
37. Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jehanno M, Viala J, et al. (2003). Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 300: 1584-1587.
38. Gotoh T, Nakahara K, Iwami M, Aoki H, Imanaka H, (1982). Studies on a new immunoactive peptide, FK-156. I. Taxonomy of the producing strains. J Antibiot (Tokyo) 35: 1280-1285.
39. Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, Nunez G, et al. (2008). A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J 27: 373-383.
40. Hasegawa M, Yamazaki T, Kamada N, Tawaratsumida K, Kim YG, Nunez G, et al. (2011). Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen. J Immunol 186: 4872-4880.
41. van Heel DA, Ghosh S, Butler M, Hunt K, Foxwell BM, Mengin-Lecreulx D, et al. (2005). Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol 35: 2471-2476.
42. Hisamatsu T, Suzuki M, Podolsky DK, (2003). Interferon-gamma augments CARD4/NOD1 gene and protein expression through interferon regulatory factor-1 in intestinal epithelial cells. J Biol Chem 278: 32962-32968.
43. Hotamisligil GS, (2006). Inflammation and metabolic disorders. Nature 444: 860-867.
44. Hruz P, Eckmann L, (2008). Caspase recruitment domain-containing sensors and adaptors in intestinal innate immunity. Curr Opin Gastroenterol 24: 108-114.
45. Hysi P, Kabesch M, Moffatt MF, Schedel M, Carr D, Zhang Y, et al. (2005). NOD1 variation, immunoglobulin E and asthma. Hum Mol Genet 14: 935-941.
46. Inamura N, Nakahara K, Kino T, Gotoh T, Kawamura I, Aoki H, et al. (1985). Activation of tumoricidal properties in macrophages and inhibition of experimentally-induced murine metastases by a new synthetic acyltripeptide, FK-565. J Biol Response Mod 4: 408-417.
47. Jimenez R, Belcher E, Sriskandan S, Lucas R, McMaster S, Vojnovic I, et al. (2005). Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. Proc Natl Acad Sci U S A 102: 4637-4642.
48. Kang MJ, Heo SK, Song EJ, Kim DJ, Han SY, Han JH, et al. (2012). Activation of Nod1 and Nod2 induces innate immune responses of prostate epithelial cells. Prostate 72: 1351-1358.
49. Kanneganti TD, Lamkanfi M, Kim YG, Chen G, Park JH, Franchi L, et al. (2007). Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 26: 433-443.
50. Kara B, Akkiz H, Doran F, Bayram S, Erken E, Gumurdullu Y, et al. (2010). The significance of E266K polymorphism in the NOD1 gene on Helicobacter pylori infection: an effective force on pathogenesis? Clin Exp Med 10: 107-112.
51. Katz JT, Shannon RP, (2006). Bacteria and coronary atheroma: more fingerprints but no smoking gun. Circulation 113: 920-922.
52. Khan PM, Correa RG, Divlianska DB, Peddibhotla S, Sessions EH, Magnuson G, et al. (2011). Identification of inhibitors of NOD1-induced nuclear factor-kappaB activation. ACS Med Chem Lett 2: 780-785.
53. Kim JG, Lee SJ, Kagnoff MF, (2004). Nod1 is an essential signal transducer in intestinal epithelial cells infected with bacteria that avoid recognition by Toll-like receptors. Infect Immun 72: 1487-1495.
54. Kim YG, Park JH, Daignault S, Fukase K, Nunez G, (2008). Cross-tolerization between Nod1 and Nod2 signaling results in reduced refractoriness to bacterial infection in Nod2-deficient macrophages. J Immunol 181: 4340-4346.
55. Kim YG, Park JH, Reimer T, Baker DP, Kawai T, Kumar H, et al. (2011). Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe 9: 496-507.
56. Kobayashi K, Inohara N, Hernandez LD, Galan JE, Nunez G, Janeway CA, et al. (2002). RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416: 194-199.
57. Koonin EV, Aravind L, (2000). The NACHT family-a new group of predicted NTPases implicated in apoptosis and MHC transcription activation. Trends Biochem Sci 25: 223-224.
58. Kumar H, Kawai T, Akira S, (2009). Toll-like receptors and innate immunity. Biochem Biophys Res Commun 388: 621-625.
59. Kupcinskas J, Wex T, Bornschein J, Selgrad M, Leja M, Juozaityte E, et al. (2011). Lack of association between gene polymorphisms of angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet 12: 112.
60. Kutikhin AG, (2011). Role of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiology. Hum Immunol 72: 955-968.
61. Laberge MA, Moore KJ, Freeman MW, (2005). Atherosclerosis and innate immune signaling. Ann Med 37: 130-140.
62. Laman JD, Schoneveld AH, Moll FL, van Meurs M, Pasterkamp G, (2002). Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques. Am J Cardiol 90: 119-123.
63. Lemaitre B, Reichhart JM, Hoffmann JA, (1997). Drosophila host defense: differential induction of antimicrobial peptide genes after infection by various classes of microorganisms. Proc Natl Acad Sci U S A 94: 14614-14619.
64. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, et al. (1996). Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 7: 330-335.
65. McDonald C, Inohara N, Nunez G, (2005). Peptidoglycan signaling in innate immunity and inflammatory disease. J Biol Chem 280: 20177-20180.
66. McGettrick AF, O'Neill LA, (2013). How metabolism generates signals during innate immunity and inflammation. J Biol Chem R113.486464.
67. McGovern DP, Hysi P, Ahmad T, van Heel DA, Moffatt MF, Carey A, et al. (2005). Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet 14: 1245-1250.
68. Marti-Carvajal A, Salanti G, Cardona AF, (2008). Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev (1): CD004388.
69. Martin G, Brunkhorst FM, Janes JM, Reinhart K, Sundin DP, Garnett K, et al. (2009). The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. Crit Care 13: R103.
70. Masumoto J, Yang K, Varambally S, Hasegawa M, Tomlins SA, Qiu S, et al. (2006). Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. J Exp Med 203: 203-213.
71. Mitchell JA, Ryffel B, Quesniaux VF, Cartwright N, Paul-Clark M, (2007). Role of pattern-recognition receptors in cardiovascular health and disease. Biochem Soc Trans 35 (Pt 6): 1449-1452.
72. Mitka M, (2011). Drug for severe sepsis is withdrawn from market, fails to reduce mortality. JAMA 306: 2439-2440.
73. Moreno L, McMaster SK, Gatheral T, Bailey LK, Harrington LS, Cartwright N, et al. (2010). Nucleotide oligomerization domain 1 is a dominant pathway for NOS2 induction in vascular smooth muscle cells: comparison with Toll-like receptor 4 responses in macrophages. Br J Pharmacol 160: 1997-2007.
74. Myhre AE, Aasen AO, Thiemermann C, Wang JE, (2006). Peptidoglycan-an endotoxin in its own right? Shock 25: 227-235.
75. Nijhuis MM, (2006). Peptidoglycan in atherosclerotic plaque formation and vulnerability. Available at: http://igitur-archive.library.uu.nl/dissertations/ 2006-0620-200920 (accessed 30/6/2013).
76. Nijhuis MM, van der Graaf Y, Melief MJ, Schoneveld AH, de Kleijn DP, Laman JD, et al. (2004). IgM antibody level against proinflammatory bacterial peptidoglycan is inversely correlated with extent of atherosclerotic disease. Atherosclerosis 173: 245-251.
77. Nishio H, Kanno S, Onoyama S, Ikeda K, Tanaka T, Kusuhara K, et al. (2011). Nod1 ligands induce site-specific vascular inflammation. Arterioscler Thromb Vasc Biol 31: 1093-1099.
78. O'Connell RM, Vaidya SA, Perry AK, Saha SK, Dempsey PW, Cheng G, (2005). Immune activation of type I IFNs by Listeria monocytogenes occurs independently of TLR4, TLR2, and receptor interacting protein 2 but involves TNFR-associated NF kappa B kinase-binding kinase 1. J Immunol 174: 1602-1607.
79. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G, (2001). Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 276: 4812-4818.
80. Opitz B, Puschel A, Schmeck B, Hocke AC, Rosseau S, Hammerschmidt S, et al. (2004). Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem 279: 36426-36432.
81. Opitz B, Forster S, Hocke AC, Maass M, Schmeck B, Hippenstiel S, et al. (2005). Nod1-mediated endothelial cell activation by Chlamydophila pneumoniae. Circ Res 96: 319-326.
82. Opitz B, Puschel A, Beermann W, Hocke AC, Forster S, Schmeck B, et al. (2006). Listeria monocytogenes activated p38 MAPK and induced IL-8 secretion in a nucleotide-binding oligomerization domain 1-dependent manner in endothelial cells. J Immunol 176: 484-490.
83. Park JH, Kim YG, McDonald C, Kanneganti TD, Hasegawa M, Body-Malapel M, et al. (2007). RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J Immunol 178: 2380-2386.
84. Parkin DM, (2006). The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030-3044.
85. Patel GP, Balk RA, (2011). Systemic steroids in severe sepsis and septic shock. Am J Respir Crit Care Med 185: 133-139.
86. Paul-Clark MJ, Sorrentino R, Bailey LK, Sriskandan S, Mitchell JA, (2008). Gram-positive and Gram-negative bacteria synergize with oxidants to release CXCL8 from innate immune cells. Mol Med 14: 238-246.
87. Paul-Clark MJ, George PM, Gatheral T, Parzych K, Wright WR, Crawford D, et al. (2012). Pharmacology and therapeutic potential of pattern recognition receptors. Pharmacol Ther 135: 200-215.
88. Regueiro V, Moranta D, Frank CG, Larrarte E, Margareto J, March C, et al. (2010). Klebsiella pneumoniae subverts the activation of inflammatory responses in a NOD1-dependent manner. Cell Microbiol 13: 135-153.
89. Rosenthal RS, Dziarski R, (1994). Isolation of peptidoglycan and soluble peptidoglycan fragments. Methods Enzymol 235: 253-285.
90. Saikku P, (2000). Chlamydia pneumoniae in atherosclerosis. J Intern Med 247: 391-396.
91. Schertzer JD, Tamrakar AK, Magalhaes JG, Pereira S, Bilan PJ, Fullerton MD, et al. (2011). NOD1 activators link innate immunity to insulin resistance. Diabetes 60: 2206-2215.
92. Schirbel A, Kessler S, Rieder F, West G, Rebert N, Asosingh K, et al. (2012). Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology 144: 613-623 e619.
93. Senft AP, Taylor RH, Lei W, Campbell SA, Tipper JL, Martinez MJ, et al. (2009). Respiratory syncytial virus impairs macrophage IFN-alpha/beta- and IFN-gamma-stimulated transcription by distinct mechanisms. Am J Respir Cell Mol Biol 42: 404-414.
94. Shaw MH, Reimer T, Kim YG, Nunez G, (2008). NOD-like receptors (NLRs): bona fide intracellular microbial sensors. Curr Opin Immunol 20: 377-382.
95. Shigeoka AA, Kambo A, Mathison JC, King AJ, Hall WF, Correia J, et al. (2010). Nod1 and nod2 are expressed in human and murine renal tubular epithelial cells and participate in renal ischemia reperfusion injury. J Immunol 184: 2297-2304.
96. Shimada K, Chen S, Dempsey PW, Sorrentino R, Alsabeh R, Slepenkin AV, et al. (2009). The NOD/RIP2 pathway is essential for host defenses against Chlamydophila pneumoniae lung infection. PLoS Pathog 5: e1000379.
97. Strober W, Murray PJ, Kitani A, Watanabe T, (2006). Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 6: 9-20.
98. Stroo I, Butter LM, Claessen N, Teske GJ, Rubino SJ, Girardin SE, et al. (2012). Phenotyping of Nod1/2 double deficient mice and characterization of Nod1/2 in systemic inflammation and associated renal disease. Biol Open 1: 1239-1247.
99. Tada H, Aiba S, Shibata K, Ohteki T, Takada H, (2005). Synergistic effect of Nod1 and Nod2 agonists with Toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun 73: 7967-7976.
100. Tamrakar AK, Schertzer JD, Chiu TT, Foley KP, Bilan PJ, Philpott DJ, et al. (2010). NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance. Endocrinology 151: 5624-5637.
101. Ting JPY, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, et al. (2008). The NLR gene family: a standard nomenclature. Immunity 28: 285-287.
102. Travassos LH, Carneiro LA, Girardin SE, Boneca IG, Lemos R, Bozza MT, et al. (2005). Nod1 participates in the innate immune response to Pseudomonas aeruginosa. J Biol Chem 280: 36714-36718.
103. Uehara A, Yang S, Fujimoto Y, Fukase K, Kusumoto S, Shibata K, et al. (2005). Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol 7: 53-61.
104. Uehara A, Fujimoto Y, Fukase K, Takada H, (2007). Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol 44: 3100-3111.
105. Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, et al. (2004). Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 5: 1166-1174.
106. Wang JE, Dahle MK, Yndestad A, Bauer I, McDonald MC, Aukrust P, et al. (2004). Peptidoglycan of Staphylococcus aureus causes inflammation and organ injury in the rat. Crit Care Med 32: 546-552.
107. Wray GM, Foster SJ, Hinds CJ, Thiemermann C, (2001). A cell wall component from pathogenic and non-pathogenic gram-positive bacteria (peptidoglycan) synergises with endotoxin to cause the release of tumour necrosis factor-alpha, nitric oxide production, shock, and multiple organ injury/dysfunction in the rat. Shock 15: 135-142.
108. Wright SD, Burton C, Hernandez M, Hassing H, Montenegro J, Mundt S, et al. (2000). Infectious agents are not necessary for murine atherogenesis. J Exp Med 191: 1437-1442.
109. Yang S, Tamai R, Akashi S, Takeuchi O, Akira S, Sugawara S, et al. (2001). Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect Immun 69: 2045-2053.
110. Yokota Y, Mine Y, Wakai Y, Watanabe Y, Nishida M, Goto S, et al. (1983). Immunoactive peptides, FK-156 and FK-565. II. Restoration of host resistance to microbial infection in immunosuppressed mice. J Antibiot (Tokyo) 36: 1051-1058.
111. Zhao L, Kwon MJ, Huang S, Lee JY, Fukase K, Inohara N, et al. (2007). Differential modulation of Nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells. J Biol Chem 282: 11618-11628.
112. Zhao L, Hu P, Zhou Y, Purohit J, Hwang D, (2011). NOD1 activation induces proinflammatory gene expression and insulin resistance in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 301: E587-E598.
113. Zilbauer M, Dorrell N, Elmi A, Lindley KJ, Schuller S, Jones HE, et al. (2007). A major role for intestinal epithelial nucleotide oligomerization domain 1 (NOD1) in eliciting host bactericidal immune responses to Campylobacter jejuni. Cell Microbiol 9: 2404-2416.